DAPT is a chemical compound used in the study of the Notch signaling pathway.[1] DAPT is a γ-secretase inhibitor. It indirectly inhibits Notch, which is a substrate for γ-secretase.[2]
| |
| Names | |
|---|---|
| Systematic IUPAC name
tert-Butyl (S)-{(2S)-2-[2-(3,5-difluorophenyl)acetamido]propanamido}phenylacetate | |
| Other names
gamma-Secretase Inhibitor IX; GSI-IX; LY-374973; N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C23H26F2N2O4 | |
| Molar mass | 432.468 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
In a mouse model of Alzheimer's disease, DAPT reduces the levels of beta-amyloid.[3]
References edit
- ^ Geling, A.; Steiner, H.; Willem, M.; Bally-Cuif, L.; Haass, C. (2002). "A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish". EMBO Reports. 3 (7): 688–694. doi:10.1093/embo-reports/kvf124. PMC 1084181. PMID 12101103.
- ^ "DAPT". Sigma-Aldrich.
- ^ Dovey, H. F.; John, V.; Anderson, J. P.; Chen, L. Z.; De Saint Andrieu, P.; Fang, L. Y.; Freedman, S. B.; Folmer, B.; Goldbach, E.; Holsztynska, E. J.; Hu, K. L.; Johnson-Wood, K. L.; Kennedy, S. L.; Kholodenko, D.; Knops, J. E.; Latimer, L. H.; Lee, M.; Liao, Z.; Lieberburg, I. M.; Motter, R. N.; Mutter, L. C.; Nietz, J.; Quinn, K. P.; Sacchi, K. L.; Seubert, P. A.; Shopp, G. M.; Thorsett, E. D.; Tung, J. S.; Wu, J.; et al. (2001). "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain". Journal of Neurochemistry. 76 (1): 173–81. doi:10.1046/j.1471-4159.2001.00012.x. PMID 11145990.